Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10138299 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Patent 10138299 was granted and assigned to Bristol-Myers Squibb on November, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Bristol-Myers Squibb
Bristol-Myers Squibb
Date Filed
June 12, 2018
Date of Patent
November 27, 2018
Patent Applicant
Bristol-Myers Squibb
Bristol-Myers Squibb
Patent Application Number
16006473
Patent Citations
‌
US Patent 10072082 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
Patent Citations Received
‌
US Patent 11767361 Method of treating lung cancer
‌
US Patent 11345752 Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
‌
US Patent 11919957 Methods of treating tumor
0
‌
US Patent 11512130 Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
‌
US Patent 10266594 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
‌
US Patent 10266595 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
‌
US Patent 10266596 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
‌
US Patent 10323093 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
‌
US Patent 10512689 Compositions comprising a combination of nivolumab and ipilimumab
‌
US Patent 10544224 Method of treating cancer using immune checkpoint inhibitor
•••
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10138299
Patent Primary Examiner
‌
Ilia I Ouspenski

Find more entities like US Patent 10138299 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo